Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Active Recombinant Human CD19 Protein, Fc-tagged, Atto 647N conjugated

Cat.No. : CD19-08H
Product Overview : Recombinant human Atto 647N conjugated CD19 (Glu21-Lys291) protein with a human IgG1 (Pro100-Lys330) Fc tag at C-terminus was expressed in chinese hamster ovary cell line.
  • Specification
  • Gene Information
  • Related Products
Description : This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
Source : CHO
Species : Human
Tag : Fc
Form : Disulfide-linked homodimer
Labeled with Atto 647N via amines
Excitation Wavelength: 647 nm
Emission Wavelength: 667 nm
Bio-activity : Measured by flow cytometry for its ability to bind anti-Human CD19 Monoclonal Antibody conjugated fluorescent beads.
Molecular Mass : 57 kDa
N-terminal Sequence Analysis : Glu21
Endotoxin : <1.0 EU/μg of the protein by the LAL method.
Purity : >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Storage : Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
6 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after opening.
3 months, -20 to -70 centigrade under sterile conditions after opening.
Storage Buffer : Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Shipping : The product is shipped with dry ice or equivalent.
Gene Name : CD19 CD19 molecule [ Homo sapiens (human) ]
Official Symbol : CD19
Synonyms : CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; T-cell surface antigen Leu-12; differentiation antigen CD19
Gene ID : 930
mRNA Refseq : NM_001770
Protein Refseq : NP_001761
MIM : 107265
UniProt ID : P15391

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
How does CAR-T cell therapy work to combat CD19-expressing cancers? 02/11/2023

CAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.

Are there any diseases associated with CD19 dysfunction? 12/07/2022

CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.

What are the potential side effects of CAR-T cell therapy targeting CD19? 01/26/2022

Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.

What are some CD19-expressing malignancies that CAR-T cell therapy can target? 07/17/2021

CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.

How effective is CAR-T cell therapy in treating CD19-expressing cancers? 08/26/2019

CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.

Customer Reviews (3)

Write a review
Reviews
01/02/2023

    The manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.

    08/18/2022

      This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.

      06/29/2016

        Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.

        Ask a Question for All CD19 Products

        Required fields are marked with *

        My Review for All CD19 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends